09.14.21
Pii has strategically invested in an expansion of its sterile fill-finish capacity and capabilities, with production lines capable of supporting large commercial scale batch sizes. Specifically, Pii has increased its investment in the Bosch Aseptic Filling Line, increasing the ability to perform Large Volume Sterile Fill-Finish production needed for manufacturing most vaccinations.
“Over the last year we have seen many vaccinations to tackle the Covid-19 pandemic. With the CDC now recommending booster shots to Americans, we are presented with a vaccine manufacturing capacity challenge,” said Kurt Nielsen, president and CEO of Pii. “Not only does our industry have to manufacture the COVID-19 Vaccines (including the booster shot), but we have to continue manufacturing the everyday vaccines including the annual Flu vaccine, Pneumovax23, Twinrix, and many more.”
Pii’s increased biologic/vaccine fill and finish capabilities include:
“Over the last year we have seen many vaccinations to tackle the Covid-19 pandemic. With the CDC now recommending booster shots to Americans, we are presented with a vaccine manufacturing capacity challenge,” said Kurt Nielsen, president and CEO of Pii. “Not only does our industry have to manufacture the COVID-19 Vaccines (including the booster shot), but we have to continue manufacturing the everyday vaccines including the annual Flu vaccine, Pneumovax23, Twinrix, and many more.”
Pii’s increased biologic/vaccine fill and finish capabilities include:
- Batch Sizes from 1L – 1000L
- Vials (2mL – 100mL) - Bosch® FWR 4080
- Clean rooms ranging from class 100 to 100,000
- Glass, COC and COP vials and syringes
- Ability to support disposable, single-use technology with varying mixing and temperature conditions
- Refrigerated Storage
